Emerging strategies to overcome resistance to third-generation EGFR inhibitors.

"Declarations Ethics approval and consent to participateThis is not applicable for this review. Consent for publicationThis is not applicable for this review. Competing interestsThe authors declare no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Competing interests The authors declare no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

"Funding This work was supported by grants from the National Natural Science Foundation of China (Grants 82037718, 81922064, 22177083), the Fundamental Research Funds for the Central Universities (SCU2022D025), 1.3.5 project for disciplines of excellent, West China Hospital, Sichuan University (ZYJC18001), the Sichuan Science and Technology Program (grant number 2022NSFSC1290, 2019YFS0003), and West China Nursing Discipline Development Special Fund Project, Sichuan University (Grant HXHL21011)."